Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment.
Surgical excision with cryotherapy is a well-established treatment option for malignant melanoma or primary acquired melanosis (PAM) with atypia of the conjunctiva and cornea. Topical chemotherapeutic agents such as mitomycin C (MMC) however, are increasingly finding use in clinical practice. A search was performed of Medline and Pubmed databases for English language articles from 1980 to the present in this field. Relevant studies were reviewed with regards to treatment regimen, rates of recurrence and metastasis, side effect profile and length of follow up. A total of 22 and 16 unique cases of biopsy proven PAM with atypia and malignant melanoma, respectively, treated with topical MMC were identified. Topical MMC was well tolerated and shows considerable promise, particularly in the treatment of diffuse PAM with atypia. However, long-term data are lacking and further studies are required.
Chalasani
Rajeev
R
Ocular Oncology Unit, Save Sight Institute, Sydney Eye Hospital, Sydney, New South Wales, Australia.
Giblin
Michael
M
Conway
R Max
RM
D000287:Administration, Topical; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D003316:Corneal Diseases / Q000188:drug therapy*; D016208:Databases, Factual; D005134:Eye Neoplasms / Q000188:drug therapy*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D008548:Melanosis / Q000188:drug therapy*; D016685:Mitomycin / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin